Pioneering The Next
Generation Of Targeted
Psychoative Medications
3 Primary Breakthroughs For The Treatment Of Mental Health Issues.
01.
Discovered an efficient, patent-pending bacterial biosynthesis process for tryptamine production.
02.
Developing a portfolio of tryptamine-derived, psychedelically inspired molecules.
03.
Demonstrated the entourage effect of certain tryptamines in a laboratory-controlled environment.
Paradigm Shift For Treating Mental Illness and Neurological Disorders
PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues.
PsyBio’s Objective Is to Develop Ground-Breaking Patient Treatments Based Upon Psychedelic Agents
PsyBio Therapeutics is creating a portfolio of unique, scientifically developed, psychoactive compounds as potential therapeutic agents for mental and neurologic health issues and developing an efficient, patent-pending bacterial biosynthesis process for tryptamine production with platform technology utilizing metabolic engineering and optimization techniques.
Research & Development Partners
Miami University, Oxford, OH
Manufacturing
Curia Global
Biose Industrie
Berkeley Lab
Analyst Coverage
Maxim Group
Noble Capital Markets
